1. Introduction {#sec1-ijms-20-03258}
===============

Insulin-like growth factor (IGF) signaling promotes cell proliferation and differentiation in normal human tissues \[[@B1-ijms-20-03258],[@B2-ijms-20-03258]\].

The IGF system comprises the IGF ligands 1 (IGF-1) and 2 (IGF-2) which modulate multiple biological processes by interacting with specific cell-surface receptors represented by IGF receptors I and II (IGF-IR and IGF-IIR) \[[@B3-ijms-20-03258],[@B4-ijms-20-03258],[@B5-ijms-20-03258],[@B6-ijms-20-03258]\]. IGF binding to IGF receptors is mediated by soluble IGF binding proteins (IGFBPs), a family of six homologous molecules (IGFBP-1-6) with high binding affinity for IGF-1 and IGF-2 \[[@B2-ijms-20-03258],[@B7-ijms-20-03258]\].

IGF-IR and IGF-IIR (IGFRs) show different structures and function. In detail, IGF-IR is a member of the receptor tyrosine kinases (RTK) and binds IGF-1 with a higher affinity than IGF-2. IGF-IR forms a tetrameric complex consisting of two alpha and two beta subunits linked by disulfide bonds through fibronectin type III (FnIII) domains. The alpha subunit localizes in the extracellular space and consists of two large homologous regions (L1 and L2) separated by a cysteine rich domain responsible for ligand binding. The beta subunit displays a trans-membrane segment and an intracellular portion containing the tyrosine kinase domain (TKD) that actively phosphorylates direct downstream targets on selected tyrosine residues \[[@B6-ijms-20-03258]\]. Unlike IGF-IR, IGF-IIR lacks catalytic activity presenting instead a monomeric structure consisting of a large extracellular portion of 15 contiguous domains followed by a short trans-membrane region. Hence, IGF-IIR shows scavenger properties towards circulating IGF-2 \[[@B6-ijms-20-03258],[@B8-ijms-20-03258]\].

An additional feature of the IGF axis is its crosstalk with insulin and insulin receptors isoforms A (IR-A) and B (IR-B). Indeed, the IGF system contributes to thyroid cancerogenesis via an IGF-2/IR-A autocrine loop as IGF-2 activates the IR-A isoform over-expressed in neoplastic thyrocytes, thus promoting their proliferation and suppressing apoptosis \[[@B9-ijms-20-03258],[@B10-ijms-20-03258]\]. However, IR-A, IR-B and IGF-IR generate hybrid tetramers (IGF-IR/IR-A) (IGF-IR/IR-B), which bind both IGF-1/-2 and insulin. Upon ligand binding, these hybrid receptors promote cell proliferation and cell adhesion but inhibit programmed cell death \[[@B11-ijms-20-03258],[@B12-ijms-20-03258],[@B13-ijms-20-03258]\].

To date, several studies have established that aberrant IGF signaling plays a critical role in cancer pathogenesis and progression. Increased expression of IGF ligands and receptors has been observed in tumors of the breast, lung, pancreas, colon, prostate, ovary, and thyroid and is usually associated with a poor prognosis \[[@B1-ijms-20-03258],[@B6-ijms-20-03258],[@B14-ijms-20-03258],[@B15-ijms-20-03258]\].

Thyroid cancer is a frequently encountered endocrine malignancy sometimes aided by exposure to multiple environmental carcinogens favoring the generation of different molecular alterations \[[@B16-ijms-20-03258],[@B17-ijms-20-03258],[@B18-ijms-20-03258],[@B19-ijms-20-03258],[@B20-ijms-20-03258]\]. Thyroid cancer mostly originates from the follicular epithelium and comprises differentiated (DTC), poorly differentiated (PDTC) and anaplastic (ATC) tumor histotypes. While DTCs are typically characterized by a favorable prognosis, PDTCs and ATCs have an unfavorable clinical course and are usually unresponsive to radioactive iodine because of their lack of the sodium iodide symporter (NIS) \[[@B21-ijms-20-03258]\]. Finally, approximately 3% of all thyroid tumors are medullary thyroid carcinomas (MTC) deriving from the neoplastic transformation of neuroendocrine C-cells \[[@B21-ijms-20-03258],[@B22-ijms-20-03258]\].

As the IGF system has been actively investigated in thyroid cancer \[[@B9-ijms-20-03258],[@B10-ijms-20-03258],[@B14-ijms-20-03258],[@B23-ijms-20-03258]\], in this review, we will provide an update focusing on the role of the IGF axis in thyroid cancer development and treatment.

2. IGF Signaling in Thyroid Cancer {#sec2-ijms-20-03258}
==================================

Deregulation of the IGF axis is emerging as a key factor promoting proliferative responses in both normal and neoplastic thyrocytes \[[@B1-ijms-20-03258],[@B10-ijms-20-03258],[@B24-ijms-20-03258],[@B25-ijms-20-03258]\]. Indeed, while both IGF-1 and IGF-IR are expressed in benign and malignant thyroid tissues \[[@B26-ijms-20-03258]\], Belfiore and colleagues reported that IGF-IR is more expressed in DTCs, allowing IGF-1 to exert a potent mitogenic effect \[[@B27-ijms-20-03258]\]. These data are in agreement with an additional manuscript describing a positive correlation between serum IGF-1 levels and the risk of developing DTCs \[[@B28-ijms-20-03258]\].

Since the IGF cascade relies on IGFBP-mediated interactions between the IGF ligands and IGF-IR, several studies have investigated if IGFBPs are involved in thyroid tumorigenesis \[[@B29-ijms-20-03258],[@B30-ijms-20-03258]\]. Indeed, experimental data suggest that IGFBPs sequester circulating IGF-1 and IGF-2, thus limiting their IGF-IR interaction and exerting a tumor suppressor activity \[[@B1-ijms-20-03258],[@B31-ijms-20-03258]\]. Hence, IGFBP-1 overexpression attenuates IGF-1 activity, at least in vitro \[[@B32-ijms-20-03258]\].

Signaling downstream of the IGF axis involves intracellular mediators contributing to cell proliferation Rat Sarcoma (RAS)/Proto-Oncogene Serine/Threonine-Protein Kinase (RAF)/Mitogen-Activated Protein Kinase inhibitors (MEK)/Extracellular Signal-Regulated Kinase (ERK), apoptosis inhibition, protein synthesis, cell cycle progression Phosphatidylinositol kinase (PI3K)/V-Akt Murine Thymoma Viral Oncogene Homolog (AKT)/Mammalian Target of Rapamycin (mTOR) and cell motility Focal Adhesion Kinase (FAK) \[[@B33-ijms-20-03258],[@B34-ijms-20-03258],[@B35-ijms-20-03258]\]. Activation of the IGF-IR receptor by IGF ligands leads to its tyrosine phosphorylation thus generating a binding site for docking proteins such as Src Homology 2 Domain Containing Transforming Protein 1 (SHC) and Insulin receptor substrates (IRSs). In turn, SHC recruitment activates RAS/RAF/ERK pathway while IRS1 and IRS2 activate the PI3K/AKT/mTOR and FAK cascades, respectively ([Figure 1](#ijms-20-03258-f001){ref-type="fig"}) \[[@B36-ijms-20-03258],[@B37-ijms-20-03258],[@B38-ijms-20-03258]\].

The involvement of the IGF axis in thyroid carcinoma is also related to crosstalk interactions between the IGF-IR and thyroid-stimulating hormone (TSH). In fact, the pro-tumorigenic effect of TSH is reduced in the absence of growth factors, but is increased by IGF-1 stimulation \[[@B10-ijms-20-03258],[@B39-ijms-20-03258],[@B40-ijms-20-03258]\]. Moreover, Sarah and colleagues reported that the crosstalk between TSH and the IGF-IR through ERK and AKT pathways up-regulates NIS expression in primary tumor thyrocytes \[[@B41-ijms-20-03258]\]. Additional data by Fukushima and colleagues indicate that cAMP-stimulating agents such as TSH induce a Nedd4-dependent ubiquitination of IRS-2 that, when associated with Nedd4, enhances IGF-dependent mitogenic effects ([Figure 2](#ijms-20-03258-f002){ref-type="fig"}) \[[@B42-ijms-20-03258]\].

An additional layer of complexity to this already composite signaling network is represented by the well documented crosstalk between the IGF axis and several RTKs including the insulin receptor (IR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), hepatocyte growth factor receptor (HGFR-proto-oncogene *MET*), the discoidin domain receptor tyrosine kinase 1 (DDR1) and the anaplastic lymphoma kinase 1 (ALK) \[[@B43-ijms-20-03258],[@B44-ijms-20-03258],[@B45-ijms-20-03258],[@B46-ijms-20-03258],[@B47-ijms-20-03258]\]. The cooperation between the IGF-IR and other RTKs activate common downstream targets such as the PI3K/AKT/mTOR and RAF/MEK/ERK pathways, thus promoting tumor proliferation and inhibiting apoptosis. Moreover, although deregulation of the IGF pathway is linked to aberrant activation of the IGFRs, several mutations of its downstream targets or additional gene rearrangements may also indirectly activate the IGF axis. Obviously, these molecular events represent a potential resistance mechanism to IGF ligand/receptor inhibitors \[[@B12-ijms-20-03258],[@B48-ijms-20-03258],[@B49-ijms-20-03258],[@B50-ijms-20-03258],[@B51-ijms-20-03258]\].

3. Targeting IGF Signaling in Thyroid Cancer {#sec3-ijms-20-03258}
============================================

Therapeutic approaches targeting the IGF axis have been investigated in many cancers as consistent evidence suggests that IGF signaling confers resistance to several anti-tumor agents \[[@B19-ijms-20-03258],[@B52-ijms-20-03258],[@B53-ijms-20-03258],[@B54-ijms-20-03258],[@B55-ijms-20-03258]\]. On the basis of these observations, IGF axis inhibitors have been combined with DNA damaging agents or different kinase inhibitors \[[@B43-ijms-20-03258],[@B56-ijms-20-03258],[@B57-ijms-20-03258],[@B58-ijms-20-03258],[@B59-ijms-20-03258],[@B60-ijms-20-03258]\]. In this section, we provide an update on the current knowledge of agents that directly (*IGF-IR direct inhibitors*) or indirectly *(IGF-IR/RTKs downstream inhibitors)* interfere with the IGF axis in thyroid carcinoma ([Figure 3](#ijms-20-03258-f003){ref-type="fig"}). Specifically, we focus on findings generated in immortalized cell lines, mouse models or in clinical trials. All published or ongoing clinical trials are reported in [Table 1](#ijms-20-03258-t001){ref-type="table"} and [Table 2](#ijms-20-03258-t002){ref-type="table"}.

3.1. IGF-IR Direct Inhibitors {#sec3dot1-ijms-20-03258}
-----------------------------

Agents exerting IGF-IR inhibition include monoclonal antibodies (mAbs) targeting IGF-IR (IGF-IR^mAbs^) and tyrosine kinase inhibitors (TKIs) binding to the IGF-IR catalytic domain (IGF-IR^TKIs^) \[[@B6-ijms-20-03258]\]. Disappointingly, clinical trials employing these agents showed modest reductions in tumor growth as multiple resistance mechanisms (an IGF2/IRA autocrine signaling loop or rising levels of circulating IGF-IR that sequesters IGF-IR inhibitors) quickly overcame their IGF-IR inhibition \[[@B54-ijms-20-03258]\]. Thus, further preclinical and clinical studies have combined IGF-IR^mAbs^ and IGF-IR^TKIs^ with different anticancer drugs.

A comprehensive description of their possible use in the preclinical or clinical settings both, in monotherapy or in combination with additional pharmacological compounds is included below.

### 3.1.1. IGF-IR^mAbs^ {#sec3dot1dot1-ijms-20-03258}

IGF-IR^mAbs^ block ligand--receptor interactions, causing receptor internalization and degradation and thereby quenching IGF-IR-mediated intracellular signaling. Several IGF-IR^mAbs^ have been generated and tested in different tumor types \[[@B6-ijms-20-03258]\] but only AVE1642, cixutumumab and ganitumab were employed for the treatment of thyroid carcinomas.

#### AVE1642

A phase I study evaluated the efficacy of the combination of AVE1642 with docetaxel in a cohort of patients affected by different tumor types including one patient with thyroid carcinoma. More than 50% of subjects enrolled in this group achieved stable disease \[[@B61-ijms-20-03258]\].

#### Cixutumumab (IMAC-A12)

Preclinical studies evaluated the efficacy of cixitumumab both in vitro and in vivo using an orthotopic mouse model of ATC \[[@B82-ijms-20-03258]\]. In this study, cixutumumab decreased IGF-IR phosphorylation in a dose dependent manner. However, this inhibition only translated in a weak reduction of cell proliferation. Interestingly, combining cixutumumab with irinotecan induced cell death in vitro and strongly reduced tumor volume in the mouse model, improving survival rates compared to irinotecan alone. Following these experimental findings, two clinical trials investigated the combination of cixutumumab and different anticancer drugs in patients with thyroid carcinoma. In a phase I trial (NCT01061749), the association of cixutumumab with the MEK1/2 inhibitor selumetinib, improved time to tumor progression \[[@B62-ijms-20-03258]\], while a nonrandomized open label phase I trial (NCT01204476) tested the association of cixutumumab with the mTOR inhibitor everolimus and octreotide in several tumor types including medullary thyroid carcinoma. To date, no results have been posted on this study.

#### Ganitumab (AMG-479)

A phase Ib basket trial investigated dual treatment with ganitumab and sorafenib or panitumumab in two patients with thyroid carcinoma \[[@B63-ijms-20-03258]\]. In this study, the association of ganitumab with sorafenib decreased tumor size, while the combination with panitumumab only reduced tumor growth. In both patients, the best clinical response detected was disease stability.

Despite the attractive role of IGF-IR^mAbs^ as anticancer agents, an important implication concerning their adverse events profile (AEs) must be considered. These pitfalls were reported in different clinical studies and include severe AEs such as early fatal toxicities \[[@B83-ijms-20-03258]\], hyper- or hypoglycemia, immune system impairment and cardiotoxicity \[[@B84-ijms-20-03258]\]. Hence, when IGF-IR^mAbs^ as used as anticancer agents, it is essential apply the correct combination with other anticancer drugs in order to reduce the AEs.

### 3.1.2. IGF-IR^TKIs^ {#sec3dot1dot2-ijms-20-03258}

IGF-IR^TKIs^ are small molecules that bind and functionally inhibit the IGF-IR catalytic domain. Currently, only results with linsitinib, NVP-ADW742, and NVP-AEW541 have been reported.

#### Linsitinib

The biological cooperation between TSH and IGF-IR was investigated in primary human thyrocytes where linsitinib inhibited TSH-mediated NIS stimulation that requires ERK and/or AKT signaling. These data highlight the importance of the TSH/IGF-IR crosstalk in thyroid cancer \[[@B41-ijms-20-03258]\].

#### NVP-ADW742

Constantine and colleagues evaluated the efficacy of NVP-ADW742 against multiple tumor cell types including thyroid carcinoma cell lines. They observed that NVP-ADW742 reduces IGF-IR phosphorylation after IGF-I stimulation and inhibits cell proliferation \[[@B85-ijms-20-03258]\].

#### NVP-AEW541

WRO thyroid cancer cells genetically modified to express the IGF-IR were implanted in thyroid glands of athymic mice and exposed to NVP-AEW541 or irinotecan, used as a reference treatment. NVP-AEW541 inhibited tumor growth more potently than irinotecan. Furthermore, NVP-AEW541 also reduced tumor angiogenesis, suggesting that IGF-IR modulates thyroid tumor microenvironment \[[@B86-ijms-20-03258]\].

3.2. Inhibitors Targeting Downstream Signaling Mediators Shared by IGF-IR/RTKs (IGF-IR/RTKs Downstream Inhibitors) {#sec3dot2-ijms-20-03258}
------------------------------------------------------------------------------------------------------------------

A further therapeutic strategy examined in thyroid carcinomas relies on agents that interfere with the complex downstream signaling generated by the crosstalk between IGF-IR and other RTKs \[[@B16-ijms-20-03258],[@B45-ijms-20-03258],[@B51-ijms-20-03258],[@B87-ijms-20-03258],[@B88-ijms-20-03258]\]. Preclinical and/or clinical results demonstrate that PI3K, AKT, mTOR, MEK and FAK inhibitors (i), alone or in combination, display therapeutic potential against thyroid carcinoma cells.

### 3.2.1. PI3Ki/AKTi/mTORi {#sec3dot2dot1-ijms-20-03258}

Aberrant activation of PI3K/AKT/mTOR signaling heavily contributes to thyroid tumorigenesis \[[@B89-ijms-20-03258],[@B90-ijms-20-03258],[@B91-ijms-20-03258]\]. Hence, these IGF signaling mediators have been extensively investigated as possible therapeutic targets for thyroid cancer treatment \[[@B92-ijms-20-03258],[@B93-ijms-20-03258]\]. A synopsis of the data available to date is summarized below.

#### Buparlisib (PI3Ki)

A phase I and a phase II clinical trial enrolling patients with refractory FTC and PDTC failed to detect reductions in tumor growth after buparlisib treatment \[[@B64-ijms-20-03258],[@B65-ijms-20-03258]\]. These observations suggested that the triple combination of a PI3Ki, an AKTi and a MEKi might be more successful. Indeed, a trial with a PI3Ki (copanlisib, taselisib and GSK2636771) combined with an AKTi (capivasertib) and a MEKi (trametinib or binimetinib) is currently ongoing (NCT02465060).

#### Ipatasertib (AKTi)

A phase I study tested the drug's efficacy in different tumor types including one patient with thyroid carcinoma. No results have yet been reported \[[@B66-ijms-20-03258]\].

#### Everolimus (mTORi)

This mTOR inhibitor generated contrasting results when employed on thyroid tumors as efficacy was mostly dependent on tumor type and stage. Indeed, while low response rates were reported in patients with locally advanced or metastatic thyroid cancer \[[@B77-ijms-20-03258]\], everolimus displayed antitumor activity in patients with advanced FTC \[[@B80-ijms-20-03258]\] or MTC \[[@B78-ijms-20-03258]\] and induced disease stability in an ATC case series \[[@B75-ijms-20-03258]\]. Finally, the combination of everolimus and cisplatin \[[@B76-ijms-20-03258]\] or sorafenib \[[@B79-ijms-20-03258]\] showed clinical efficacy both in DTCs and MTCs.

#### Sirolimus (mTORi)

A retrospective study evaluated the efficacy of sirolimus and cyclophosphamide in patients with advanced differentiated thyroid carcinoma. The association was well tolerated, but no differences in progression-free survival were detected between patients in the experimental arm and those allocated to the control group (receiving standard of care for disease progression) \[[@B94-ijms-20-03258]\].

#### Temsirolimus (mTORi)

The ability of temsirolimus to interfere with thyroid tumor growth was described in association with anti-angiogenic agent (trebaninib) or multikinase inhibitor (sorafenib). Specifically, a phase I trial enrolling patients with different tumor types including one with thyroid carcinoma found that the association of temsirolimus and trebaninib induced a partial response \[[@B81-ijms-20-03258]\]. A more potent inhibition of thyroid cancer growth was achieved by combining temsirolimus and sorafenib. In detail, 36 patients affected by metastatic radioiodine-refractory thyroid cancer received the two drugs attaining stable disease in 58% of cases, a 1-year progression-free survival rate of 30.5% and an overall survival of 24.6 months \[[@B79-ijms-20-03258]\]. Moreover, an open label phase I trial is ongoing to evaluate the efficacy of temsirolimus associated with bevacizumab or vinorelbine in patients with advanced thyroid cancer (NCT01552434 and NCT01155258).

### 3.2.2. MEKi {#sec3dot2dot2-ijms-20-03258}

Aberrant activation of intracellular signaling involving the MEK pathway contributes to thyroid tumorigenesis since MEK inhibition favors differentiation of radioiodine-refractory DTCs by restoring NIS expression \[[@B86-ijms-20-03258],[@B95-ijms-20-03258],[@B96-ijms-20-03258]\]. Hence, a number of specific MEKi have been evaluated in preclinical and clinical studies including several samples/patients diagnosed with thyroid cancer \[[@B97-ijms-20-03258],[@B98-ijms-20-03258],[@B99-ijms-20-03258]\].

#### Binimetinib and Pimasertib

Two phase I studies investigated the efficacy of binimetinib and the association of pimasertib with temsirolimus in patients with advanced solid tumors including thyroid cancer. However, no data have yet been reported with the exception of a case report describing a patient receiving binimetinib that achieved a partial response (tumor shrinkage \>30%) \[[@B69-ijms-20-03258],[@B70-ijms-20-03258]\].

#### Selumetinib

In a clinical trial (NCT009700359) enrolling 24 patients with thyroid cancer refractory to radioiodine, selumetinib generated clinically meaningful increases in iodine uptake \[[@B100-ijms-20-03258]\]. This important observation, spurred an additional study that is evaluating Iodine-131 combined with selumetinib (NTC02393690). In a phase I clinical trial, Infante and colleagues reported a series of patients with different tumor types (two thyroid carcinomas) exposed to the association of selumetinib and temsirolimus. The entire cohort displayed stable disease status \[[@B71-ijms-20-03258]\]. Finally, a phase II study that accrued 39 patients with radioiodine-refractory PTCs demonstrated that selumetinib was ineffective in patients with the *B-RAF*^V600E^ mutation \[[@B72-ijms-20-03258]\].

#### Trametinib

This compound is an allosteric MEK inhibitor with documented anti-tumor activity against thyroid cancer. A phase I dose-escalating basket trial evaluated trametinib efficacy in five patients with thyroid carcinomas. All patients achieved stable disease or partial responses \[[@B73-ijms-20-03258]\]. A phase IB trial assessed the combination of trametinib and everolimus in 67 patients with advanced solid tumors (one diagnosed with thyroid cancer), but the response achieved by this patient has not been reported \[[@B74-ijms-20-03258]\]. Several additional clinical studies combining trametinib with other anticancer drugs in thyroid cancer are presently ongoing.

### 3.2.3. FAKi {#sec3dot2dot3-ijms-20-03258}

Although both in vitro and in vivo models have demonstrated an active role for FAK in thyroid tumorigenesis \[[@B16-ijms-20-03258],[@B101-ijms-20-03258],[@B102-ijms-20-03258],[@B103-ijms-20-03258],[@B104-ijms-20-03258]\], no meaningful data have been reported in thyroid cancer patients. Two phase-I studies employing the FAK inhibitors VS-6063 and GSK2256098 in three patients with advanced thyroid cancer failed to describe any clinically significant results. This observation may be explained by the observation that blocking FAK prevents tumor invasion but likely doesn't influence tumor size \[[@B67-ijms-20-03258],[@B68-ijms-20-03258]\]. To date, no clinical trials investigating FAK inhibitors in thyroid cancer are available.

4. Conclusions {#sec4-ijms-20-03258}
==============

In the last few years, the incidence of thyroid carcinoma is increasing across multiple countries \[[@B31-ijms-20-03258]\]. Although most thyroid tumors are DTCs with good prognosis, PDTCs and ATCs display unfavorable outcomes requiring new therapeutic options \[[@B51-ijms-20-03258]\].

Increased understanding of cancer biology has led to the development of anticancer drugs targeting specific oncogenic substrates such as AKT, BCR-ABL1, EGFR, MET, and the IGF-IR. Since the IGF system is often deregulated in thyroid cancer, it has been considered an attractive pharmacological target for this disease \[[@B10-ijms-20-03258]\]. However, compounds that directly interfere with IGF-IR activity failed to demonstrate meaningful clinical activity \[[@B6-ijms-20-03258]\]. Different hypotheses have been developed to explain their weak efficacy in thyroid carcinomas including: (i) the persistent activation of an IGF-2-IR-A autocrine loop favoring cancer progression \[[@B6-ijms-20-03258],[@B105-ijms-20-03258]\], (ii) IGF-IR crosstalk with other RTKs \[[@B51-ijms-20-03258]\], compensatory intracellular signaling causing loss of therapeutic efficacy \[[@B106-ijms-20-03258]\] and (iii) molecular alterations in RTK downstream targets (e.g., RAS or B-RAF) driving cell growth regardless of IGF inhibition \[[@B33-ijms-20-03258]\].

In this complex scenario, combined targeted regimens may overcome these resistance phenomena and improve patient response rates \[[@B21-ijms-20-03258],[@B107-ijms-20-03258],[@B108-ijms-20-03258],[@B109-ijms-20-03258],[@B110-ijms-20-03258]\]. Thus, dual inhibition approaches using both IGF-IR and RTKs antagonists have been investigated, but these combinations have resulted in disease stability without relevant tumor shrinkage.

Among the most promising pharmacological agents targeting downstream signaling mediators shared by both IGF-IR and RTKs, the combination of anti-mTOR compounds with different kinase inhibitors has generated encouraging reductions in tumor growth \[[@B48-ijms-20-03258]\]. MEK inhibitors could also represent a possible therapeutic approach as these drugs may restore NIS expression in patients with radioiodine-refractory thyroid carcinoma.

In summary, while multiple pharmacological approaches aimed against the IGF axis have been actively investigated for the treatment of PDTCs and ATCs, further biological studies and additional compounds and/or pharmacological strategies will be required to significantly improve the outcome of these aggressive forms of thyroid cancer.
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![Schematic representation of the IGF-IR downstream signaling. Activation of IGF-IR is triggered by IGF1/2 ligands and modulated by IGFBPs. After ligand binding, IGF-IR recruits docking proteins including IRSs and SHC which induce the activation of intracellular modulators involved in: cell growth (RAS/RAF/MEK/ERK), protein synthesis, cell cycle progression (PI3K/AKT/mTOR) and cell motility \[[@B33-ijms-20-03258]\]. Activated IGF-IR also inhibits apoptosis.](ijms-20-03258-g001){#ijms-20-03258-f001}

![Working model depicting how the TSH/Nedd4/IRS2 axis improves IGF mitogenic activity. cAMP-stimulating agents such as TSH, promote Nedd4-dependent ubiquitination of IRS-2 thereby assembling a Nedd4-IRS-2 complex that enhances IGF-dependent mitogenic signaling. AC: Adenylyl cyclase; Gs: G Protein.](ijms-20-03258-g002){#ijms-20-03258-f002}

![Schematic representation of direct and indirect pharmacological agents targeting the IGF axis that have been investigated in thyroid cancer. IGF-IR direct inhibitors, IGF-IR^mAbs^ (**a**) and IGF-IR^TKIs^ (**b**) reduce IGF downstream signaling. IGF-IR/RTK downstream inhibitors targeting PI3K (**c**), AKT (**d**) and mTOR (**e**) restore apoptosis while blocking protein synthesis and cell cycle progression. MEK (**f**) and FAK (**g**) inhibitors interfere with cell motility, respectively, while EGFR inhibitors (**h**), MK (multi-kinase) inhibitors (**i**) and RTK^mAbs^ (**m**) hinder the cooperation between the IGF-IR and other RTKs.](ijms-20-03258-g003){#ijms-20-03258-f003}

ijms-20-03258-t001_Table 1

###### 

Clinical studies with published data.

  Class of Drugs             Drug Name                  Published Data             Phase            Tumor Type                 N°\*                                   Regimen
  -------------------------- -------------------------- -------------------------- ---------------- -------------------------- -------------------------------------- -------------------
  IGF-IRi                    AVE1642                    \[[@B61-ijms-20-03258]\]   I                Advanced Solid             1                                      AVE1642+Docetaxel
  Cixutumumab                \[[@B62-ijms-20-03258]\]   I                          Advanced Solid   4                          Cixutumumab + Selumetinib              
  Ganitumab                  \[[@B63-ijms-20-03258]\]   I                          Advanced Solid   2                          Ganitumab + Sorafenib or Panitumumab   
  PI3Ki                      Buparlisib                 \[[@B64-ijms-20-03258]\]   I                Advanced Solid             1                                      Monotherapy
  \[[@B65-ijms-20-03258]\]   II                         FTC + PDTC                 43               Monotherapy                                                       
  AKTi                       Ipatasertib                \[[@B66-ijms-20-03258]\]   I                Advanced Solid             1                                      Monotherapy
  FAKi                       VS-6063                    \[[@B67-ijms-20-03258]\]   I                Advanced Solid             1                                      Monotherapy
  GSK2256098                 \[[@B68-ijms-20-03258]\]   I                          Advanced Solid   2                          Monotherapy                            
  MEKi                       Binimetinib                \[[@B69-ijms-20-03258]\]   II               Advanced Solid             2                                      Monotherapy
  Pimasertib                 \[[@B70-ijms-20-03258]\]   I                          Advanced Solid   1                          Pimasertib+Temsirolimus                
  Selumetinib                \[[@B71-ijms-20-03258]\]   I                          Advanced Solid   2                          Selumetinib + Temsirolimus             
  \[[@B72-ijms-20-03258]\]   I                          PTC                        39               Monotherapy                                                       
  Trametinib                 \[[@B73-ijms-20-03258]\]   I                          Advanced Solid   5                          Monotherapy                            
                             \[[@B74-ijms-20-03258]\]   I                          Advanced Solid   1                          Trametinib + Everolimus                
  mToRi                      Everolimus                 \[[@B75-ijms-20-03258]\]   II               ATC                        5                                      Monotherapy
  \[[@B76-ijms-20-03258]\]   I                          Advanced Solid             7                Everolimus + Cisplatin                                            
  \[[@B77-ijms-20-03258]\]   II                         DTC+ATC+MTC                40               Monotherapy                                                       
  \[[@B78-ijms-20-03258]\]   II                         MTC                        7                Monotherapy                                                       
  \[[@B79-ijms-20-03258]\]   II                         DTC+MTC                    41               Everolimus + Sorafenib                                            
  \[[@B80-ijms-20-03258]\]   II                         DTC+ATC                    28               Monotherapy                                                       
  Temsirolimus               \[[@B81-ijms-20-03258]\]   I                          Advanced Solid   1                          Temsirolimus + Trebananib              
  \[[@B79-ijms-20-03258]\]   II                         DTC+ATC                    36               Temsirolimus + Sorafenib                                          

N°\* of thyroid cancer patients in each trial; FTC Follicular Thyroid Cancer; PDTC Poorly Differentiated Thyroid Cancer, MTC Medullary Thyroid Cancer, DTC Differentiated Thyroid Cancer, ATC Anaplastic Thyroid Cancer.
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###### 

Ongoing or completed yet unpublished clinical trials.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intervention                                 Population                                                                                                                    Design                                    Pts (n)     Primary End Point   Status                   Identifier
  -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------- ------------------- ------------------------ -------------
  Cixutumumab^IGF-IRmAb^ Everolimus^mTORi^\    Advanced low- or intermediate-grade neuroendocrine cancers                                                                    Nonrandomized,\                           27\         DLTs, PD, PK, SP    Completed                NCT01204476
  Octreotide ^somatostatin\ analogue^                                                                                                                                        Open label, phase I                       actual                                                   

  Binimetinib ^MEKi^\                          Genetic testing-directed targeted therapy in patients with advanced refractory solid tumors, lymphomas, or multiple myeloma   Nonrandomized,\                           6452\       ORR                 Recruiting               NCT02465060
  Capivasertib ^Akt^\                                                                                                                                                        Open label, phase II\                     estimated                                                
  Copanlisib ^PI3Ki^\                                                                                                                                                        (molecular analysis for therapy choice)                                                            
  Taselisib^PI3Ki^\                                                                                                                                                                                                                                                             
  GSK2636771^PI3Ki^\                                                                                                                                                                                                                                                            
  Trametinib ^MEKi^                                                                                                                                                                                                                                                             

  Everolimus ^mTORi^\                          Metastatic differentiated thyroid cancer progressed on Sorafenib                                                              Nonrandomized,\                           40\         ORR, PFS            Active, not Recruiting   NCT01263951
  Sorafenib ^MKi^                                                                                                                                                            Open label, phase II                      estimated                                                

  Everolimus ^mTORi^\                          Advanced thyroid cancer naive to m-TOR inhibitors or Sorafenib                                                                Nonrandomized,\                           41\         ORR                 Active, not Recruiting   NCT01141309
  Sorafenib ^MKi^                                                                                                                                                            Open label, phase II                      actual                                                   

  Everolimus ^mTORi^\                          Radioiodine-refractory differentiated and medullary thyroid cancer                                                            Randomized,\                              42\         ORR                 Completed                NCT01270321
  Pasireotide ^somatostatin\ analogue^                                                                                                                                       Open label, phase II                      actual                                                   

  Everolimus ^mTORi^                           Radioiodine-refractory thyroid cancer                                                                                         Nonrandomized,\                           33\         PFS                 Active, not Recruiting   NCT00936858
                                                                                                                                                                             Open label, phase II                      estimated                                                

  Everolimus ^mTORi^\                          Advanced radioiodine-refractory Hurthle cell thyroid cancer                                                                   Randomized,\                              34\         PFS                 Recruiting               NCT02143726
  Sorafenib ^MKi^                                                                                                                                                            Open label, phase II                      estimated                                                

  Everolimus ^mTORi^\                          Metastatic differentiated thyroid cancer progressed on Lenvatinib                                                             Nonrandomized,\                           40\         PFS                 Recruiting               NCT03139747
  Lenvatinib ^MKi^                                                                                                                                                           Open label, phase II                      estimated                                                

  Everolimus ^mTORi^\                          Advanced medullary thyroid cancer                                                                                             Nonrandomized,\                           19\         PFS                 Completed                NCT01625520
  Pasireotide ^somatostatin\ analogue^                                                                                                                                       Open label, phase II                      actual                                                   

  Everolimus ^mTORi^                           Locally advanced or metastatic thyroid cancer                                                                                 Nonrandomized,\                           40\         ORR                 Completed                NCT01164176
                                                                                                                                                                             Open label, phase II                      actual                                                   

  Everolimus ^mTORi^\                          Advanced cancer with *EGFR* mutation/amplification, *HER2* mutation/amplification, *HER3/4* mutation or *KRAS* mutation       Nonrandomized,\                           120\        DLTs                Recruiting               NCT03065387
  Neratinib ^EGFRi^\                                                                                                                                                         Open label, phase I                       estimated                                                
  or\                                                                                                                                                                                                                                                                           
  Neratinib ^EGFRi^\                                                                                                                                                                                                                                                            
  Trametinib ^MEKi^                                                                                                                                                                                                                                                             

  Everolimus ^mTORi^\                          Advanced solid tumors                                                                                                         Nonrandomized,\                           96\         DLTs, SP            Completed                NCT00655655
  Vatalanib ^VEGFi^                                                                                                                                                          Open label, phase I                       estimated                                                

  Bevacizumab^VEGFmAbs^ Temsirolimus ^mTORi^   Advanced or metastatic malignancies or other benign diseases                                                                  Nonrandomized,\                           216\        DLTs                Recruiting               NCT01552434
                                                                                                                                                                             Open label, phase I                       estimated                                                

  Temsirolimus ^mTORi^\                        Unresectable or metastatic solid tumors                                                                                       Nonrandomized,\                           19\         DLTs, ORR           Completed                NCT01155258
  Vinorelbine                                                                                                                                                                Open label, phase I                       actual                                                   

  Ciclophosfamide\                             Metastatic, RAI-refractory, differentiated thyroid cancer                                                                     Nonrandomized,\                           19\         ORR                 Recruiting               NCT03099356
  Sirolimus ^mTORi^                                                                                                                                                          Open label, phase II                      estimated                                                

  Grapefruit juice\                            Advanced malignancies                                                                                                         Nonrandomized,\                           41\         PK                  Completed                NCT00375245
  Sirolimus ^mTORi^                                                                                                                                                          Open label, phase Ib                      actual                                                   

  Iodine I-131\                                Recurrent or metastatic thyroid cancer                                                                                        Randomized,\                              60\         ORR                 Recruiting               NCT02393690
  Selumetinib ^MEKi^                                                                                                                                                         Double blind, phase II                    estimated                                                

  Olaparib ^PARPi^\                            Endometrial, ovarian and other solid tumors with RAS pathway alterations and ovarian tumors with resistance to PARPis         Nonrandomized,\                           90\         DLTs                Recruiting               NCT03162627
  Selumetinib ^MEKi^                                                                                                                                                         Open label, phase I                       estimated                                                

  Paclitaxel\                                  Anaplastic thyroid cancer                                                                                                     Nonrandomized,\                           12\         PFS                 Recruiting               NCT03085056
  Trametinib ^MEKi^                                                                                                                                                          Open label, early phase I                 estimated                                                

  Dabrafenib ^BRAFi^\                          Recurrent thyroid cancer                                                                                                      Randomized,\                              53\         ORR                 Active, not Recruiting   NCT01723202
  Trametinib ^MEKi^                                                                                                                                                          Open label, phase II                      actual                                                   

  Dabrafenib ^BRAFi^\                          Refractory metastatic differentiated thyroid cancer with *RAS* or *BRAF*^V600E^ mutations                                     Nonrandomized,\                           87\         ORR                 Recruiting               NCT03244956
  Trametinib ^MEKi^                                                                                                                                                          Open label, phase II                      estimated                                                

  Pazopanib ^MKi^\                             Advanced solid tumors enriched for patients with differentiated thyroid cancer, soft tissue sarcoma, and cholangiocarcinoma   Nonrandomized,\                           89\         DLTs, SP            Completed                NCT01438554
  Trametinib ^MEKi^                                                                                                                                                          Open label, phase I                       actual                                                   

  RAI\                                         Mutant *RAS* or wild-type *RAS*/*RAF*, RAI-refractory recurrent and/or metastatic thyroid cancer                              Nonrandomized,\                           35\         PFS, ORR            Recruiting               NCT02152995
  Trametinib^MEKi^                                                                                                                                                           Open label, phase II                      estimated                                                

  Cobimetinib^MEKi^                            Differentiated, poorly differentiated and anaplastic thyroid carcinomas                                                       Nonrandomized,\                           50\         OS                  Recruiting               NCT03181100
                                                                                                                                                                             Open label, phase II                      estimated                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Acronyms: Complete remission rate (CRR); Dose-limiting toxicities (DLTs); Objective response rate (ORR); Overall survival (OS); Pharmacodynamic (PD); Pharmacokinetics (PK); Progression-free survival (PFS); Safety profile (SP).

[^1]: These authors contributed equally to this work.
